Hims reports Q4 earnings beat, revenue miss
The report comes as the company has faced mounting legal troubles related to its short-lived Wegovy pill copy.
Hims & Hers reported mixed financial results and gave a lukewarm full year guidance, moves that come after a tumultuous stretch for the telehealth company.
For the last three months of 2025, Hims & Hers reported:
$0.08 earnings per share, compared to $0.04 analysts polled by FactSet were expecting.
$617.8 million revenue, compared to $619 million analysts were penciling in.
For the full-year 2026, the company expects:
Revenue to hit between $2.7 billion and $2.9 billion, compared to $2.74 billion analysts are currently expecting.
Adjusted EBITDA between $300 million and $375 million, compared to $369 million the Street is expecting.
The earnings report comes as the company faced massive blowback from regulators after it rolled out a copy of Novo Nordisk’s Wegovy pill early this month. Hims is now facing a patent infringement lawsuit from Novo as well as potential charges by the Department of Justice. The company said its outlook assumes that it will continue to be able to sell copycat versions of Novo's drugs.
The stock has also taken a hit: it is down more than 50% since the start of the year, with more than 30% of that drawdown coming after Hims announced the Wegovy pill copies. The stock fell about 2% in after-hours trading following the report.
As its weight loss segment sits in a precarious place, the company has focused on expanding into new treatments and geographies.
While the company does not break out revenue by treatment segment, it did say that more than half of its revenue in 2025 came from "non-GLP-1 offerings." It has added hormone treatments and labs, including a cancer detection test from Grail. Hims announced last week that it would acquire Eucalyptus, an Australian digital health company, in a deal valued up to $1.15 billion.
Last year, Hims bought Zava, a UK-based peer with a presence in France, Ireland, and Germany, for $265.7 million. It also announced that it would launch in Canada this year offering generic Wegovy. The Eucalyptus acquisition puts Hims in new markets — like Australia and Japan — and gives it a wider presence in other international markets like the United Kingdom, Germany, and Australia.
The company also broke out its international revenue for the first time: In 2025 if it brought in $133.9 million from outside the US, compared to $26.8 million in 2024.
